Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer - Concepedia

Concepedia

Publication | Open Access

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer

DOI Full Paper Access

30

Citations

24

References

2024

Year

Komal Jhaveri, Melissa Accordino, Philippe L. Bédard, Andrés Cervantes, Valentina Gambardella, Erika Hamilton, Antoîne Italiano, Kevin Kalinsky, Ian E. Krop, Mafalda Oliveira,

Journal of Clinical Oncology

Abstract

Inavolisib plus palbociclib and ET demonstrated a manageable safety profile, lack of DDIs, and promising preliminary antitumor activity.

References

	Year	Citations

Page 1